Abstract
The radiobiology of radioimmunotherapy is an important determinant of both the toxicity and the efficacy associated with the treatment of B-cell non-Hodgkin's lymphoma with radiolabeled anti-CD20 monoclonal antibodies. The properties of the target, CD20, and the mechanisms of action of both the monoclonal antibodies and the associated exponentially decreasing low-dose-rate radiotherapy are described. The radiation dose and dose-rate effects are discussed and related to both the tumor responses and normal organ toxicity. Finally, the use of either unlabeled or radiolabeled anti-CD20 monoclonal antibodies as a component of combined modality therapy (including the sequential or concurrent use of sensitizers) and future directions of the field are discussed.
MeSH terms
-
Antibodies, Monoclonal / therapeutic use*
-
Antigens, CD20 / immunology
-
Antineoplastic Agents / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Combined Modality Therapy
-
Cyclophosphamide / administration & dosage
-
Doxorubicin / administration & dosage
-
Humans
-
Iodine Radioisotopes / therapeutic use
-
Lymphoma, B-Cell / radiotherapy*
-
Prednisone / administration & dosage
-
Radiation-Sensitizing Agents / therapeutic use
-
Radiobiology
-
Radioimmunotherapy / methods*
-
Vincristine / administration & dosage
-
Yttrium Radioisotopes / therapeutic use
Substances
-
Antibodies, Monoclonal
-
Antigens, CD20
-
Antineoplastic Agents
-
Iodine Radioisotopes
-
Radiation-Sensitizing Agents
-
Yttrium Radioisotopes
-
ibritumomab tiuxetan
-
Vincristine
-
Doxorubicin
-
Cyclophosphamide
-
tositumomab I-131
-
Prednisone